Thursday, September 25
17:30-18:00 Evidence for treatment of chronic GvHD using ECP – A future backbone for GvHD Therapy
Industry-supported Meet the Expert Session by Therakos
18:00 Welcome Reception
Friday, September 26
08:15-08:30 Good Morning Coffee
08:30-08:45 Welcome Note
08:45-10:15 Session 1: CAR-T Cell Therapy
10:15-10:45 Coffee Break, Poster Viewing and Visit Exhibition
10:45-12:15 Session 2: Stem Cell Transplantation in AML
12:15-13:15 Session 3: Post-Transplant Lymphoproliferative Disorders
13:15-14:00 Lunch Break, Poster Viewing and Visit Exhibition
14:00-15:00 Controversy in FLT3-AML: Can MRD guide the way to clinical decisions along the patient pathway?
Industry-supported Lunch Symposium by Daiichi Sankyo
15:00-15:45 Session 4: Immunotherapy in AML
15:45-16:15 Coffee Break, Poster Viewing and Visit Exhibition
16:15-17:45 Session 5: Myelodysplastic Neoplasms (MDS)
Saturday, September 27
08:30-09:30 Session 6: A CME Symposium on Multiple Myeloma
09:30-10:00 Coffee Break, Poster Viewing and Visit Exhibition
10:00-11:00 Should extended CMV prophylaxis for seropositive patients become the new standard in clinical practice?
Industry-supported Symposium by MSD
11:00-12:20 Session 7: GvHD Prophylaxis
12:20-13:00 Lunch Break, Poster Viewing and Visit Exhibition
13:00-14:30 Redefining what’s possible in GvHD care: How can pathophysiology guide treatment and its intensification?
Industry-supported Lunch Symposium by Sanofi
14:30-15:50 Session 8: Spleen in MPN & Cord for GVL
15:50-16:05 Coffee Break, Poster Viewing and Visit Exhibition
16:05-17:25 Session 9: Prevention of GvHD
17:25-18:45 Session 10: GvHD Treatment
18:45 Poster Walk and Awards Session
(Poster Area)
Sunday, September 28
09:00-10:30 Session 11: Future of Trials and GvHD
10:30-11:00 Coffee Break
11:00-12:30 Session 12: Autoimmune Diseases and Follicular Lymphoma
12:30 Closing Remarks
Congress Co-Chairs